Catalyst Pharmaceuticals, Inc. (CPRX): Price and Financial Metrics


Catalyst Pharmaceuticals, Inc. (CPRX): $5.90

0.01 (+0.17%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

CPRX POWR Grades


  • CPRX scores best on the Value dimension, with a Value rank ahead of 97.66% of US stocks.
  • CPRX's strongest trending metric is Momentum; it's been moving down over the last 31 weeks.
  • CPRX ranks lowest in Momentum; there it ranks in the 5th percentile.

CPRX Stock Summary

  • The ratio of debt to operating expenses for Catalyst Pharmaceuticals Inc is higher than it is for about just 10.07% of US stocks.
  • CPRX's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 9.51% of US stocks.
  • With a year-over-year growth in debt of 626.4%, Catalyst Pharmaceuticals Inc's debt growth rate surpasses 97.59% of about US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Catalyst Pharmaceuticals Inc are ACLS, SANM, UEIC, ERII, and FORM.
  • Visit CPRX's SEC page to see the company's official filings. To visit the company's web site, go to www.catalystpharma.com.

CPRX Valuation Summary

  • CPRX's EV/EBIT ratio is 11.1; this is 58.43% lower than that of the median Healthcare stock.
  • Over the past 178 months, CPRX's price/earnings ratio has gone up 38.6.
  • CPRX's EV/EBIT ratio has moved up 40.5 over the prior 178 months.

Below are key valuation metrics over time for CPRX.

Stock Date P/S P/B P/E EV/EBIT
CPRX 2021-04-26 4 2.8 6.4 8.3
CPRX 2011-07-14 NA 5.4 -7.6 -6.1
CPRX 2009-12-22 NA 2.5 -1.2 -0.7
CPRX 2009-03-31 NA 2.3 -2.3 -1.2
CPRX 2009-03-26 NA 2.3 -2.3 -1.2
CPRX 2008-05-01 NA 2.8 -10.9 -7.0

CPRX Growth Metrics

  • The year over year cash and equivalents growth rate now stands at 25.13%.
  • Its year over year revenue growth rate is now at 0.96%.
  • Its 5 year net cashflow from operations growth rate is now at 386.73%.
Over the past 30 months, CPRX's revenue has gone up $120,141,331.

The table below shows CPRX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-03-31 120.1413 41.63579 72.21998
2020-12-31 119.0728 45.03486 74.983
2020-09-30 118.1804 44.22074 71.47558
2020-06-30 119.7612 49.03225 41.76589
2020-03-31 118.9944 49.78731 42.94586
2019-12-31 102.3063 34.61147 31.87534

CPRX Price Target

For more insight on analysts targets of CPRX, see our CPRX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $7.50 Average Broker Recommendation 1.5 (Moderate Buy)

CPRX Stock Price Chart Interactive Chart >

Price chart for CPRX

CPRX Price/Volume Stats

Current price $5.90 52-week high $6.22
Prev. close $5.89 52-week low $2.88
Day low $5.83 Volume 519,919
Day high $6.06 Avg. volume 1,446,647
50-day MA $5.65 Dividend yield N/A
200-day MA $4.34 Market Cap 609.85M

Catalyst Pharmaceuticals, Inc. (CPRX) Company Bio


Catalyst Pharmaceuticals focuses on the development and commercialization of prescription drugs targeting rare neurological diseases and disorders. The company was founded in 2002 and is based in Coral Gables, Florida.


CPRX Latest News Stream


Event/Time News Detail
Loading, please wait...

CPRX Latest Social Stream


Loading social stream, please wait...

View Full CPRX Social Stream

Latest CPRX News From Around the Web

Below are the latest news stories about Catalyst Pharmaceuticals Inc that investors may wish to consider to help them evaluate CPRX as an investment opportunity.

Catalyst Pharmaceuticals to Hold Second Quarter 2021 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, August 10th, 2021

CORAL GABLES, Fla., July 26, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases, today announced that it will release second quarter 2021 financial results after market close on Monday, August 9, 2021. Further, Catalyst management will host an investment-community conference call a

Yahoo | July 26, 2021

What Type Of Shareholders Own The Most Number of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares?

A look at the shareholders of Catalyst Pharmaceuticals, Inc. ( NASDAQ:CPRX ) can tell us which group is most powerful...

Yahoo | July 23, 2021

Catalyst Pharmaceuticals Announces Issuance of U.S. Patent 11,060,128 a Method of Use Patent with Claims Covering Firdapse®

New patent bolsters intellectual property protection for Firdapse®First in a family of four pending patents for Firdapse® to issue CORAL GABLES, Fla., July 19, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases, today announced that the United States Patent and Trademark Office (

Yahoo | July 19, 2021

Catalyst Pharmaceuticals Expands Leadership Team with Appointment of Preethi Sundaram, Ph.D. as Chief Product Development Officer

CORAL GABLES, Fla., July 06, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases, today announced the appointment of Dr. Preethi Sundaram as Chief Product Development Officer. This position will report to the Chief Executive Officer.

Intrado Digital Media | July 6, 2021

Catalyst Pharmaceuticals Appoints Pharmaceutical Executive

Catalyst Pharmaceuticals Appoints Pharmaceutical Executive Molly Harper to its Board of Directors GlobeNewswire

Intrado Digital Media | July 3, 2021

Read More 'CPRX' Stories Here

CPRX Price Returns

1-mo 2.08%
3-mo 28.82%
6-mo 62.09%
1-year 29.96%
3-year 104.15%
5-year 719.44%
YTD 76.65%
2020 -10.93%
2019 95.31%
2018 -50.90%
2017 272.38%
2016 -57.14%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.846 seconds.